Oral Communication
OC 17 Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in real-world setting in ART-naive patients: data from ICONA Cohort. A. Tavelli, G. Marchetti, A. Vergori, E. Quiros Roldan, V. Malagnino, F. Vichi, M. Lichtner, S. Nozza, R. Rossotti, L. Sarmati, F. Bai, A. Di Biagio, A. Antinori, A. d'Arminio Monforte, for ICONA Foundation Study Group
OC 18 Effectiveness of first-line lamivudine-dolutegravir (3TC-DTG) antiretroviral therapy (ART) in persons living with HIV (PLWH): real-life data from ICONA Foundation Cohort. S. Lo Caputo, A. Cozzi-Lepri, R. Gagliardini, E. Schiaroli, G. Orofino, A. Vergori, F. Maggiolo, N. Gianotti, A. Castagna, A. Cingolani, A. Antinori, A. d'Arminio Monforte, for ICONA Foundation Study Group
OC 19 Body weight and plasma lipids changes in person living with HIV (PLWH) starting double or triple INSTI-based cART regimens. F. Bai, M. Ponzano, F. Bovis, A. di Biagio, G. Guaraldi, A. Rodanò, C. Stingone, R. Marocco, D. Leoni, A. Cozzi-Lepri, A. d’Arminio Monforte, G. Marchetti
OC 21 Sexual and reproductive unmet clinical needs in Italian women living with HIV: results from Marilyn study. G.V. Calvino, M. Errico, A. Tavelli, M.L. Cosmaro, A. Perziano, A. Bove, L. Taramasso, I. Mastrorosa, M. Di Gaetano, M. Ferrara, M. Cernuschi, M. Lichtner, A.d’Arminio Monforte, A. Cingolani, for Icona Foundation Study Group
OC 60 Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL A. Cozzi-Lepri, A. Tavelli, L. Taramasso, D. Barbanotti , G. Lapadula, N. Bobbio, S. Piconi, G. Guaraldi, A. Di Biagio, C. Muccini, A. Antinori, A. d'Arminio Monforte, on behalf of ICONA Foundation Study group
OC 72 Impact of COVID-19 pandemic on retention in care of native and migrant PLWH in ICONA Cohort. R. Gagliardini, A. Giacomelli, G. Bozzi, A. D’Arminio Monforte, A. Tavelli, V. Mazzotta, E. Bruzzesi, A. Cervo, A. Saracino, C. Mussini, E. Girardi, A. Cozzi-Lepri, A. Antinori, on behalf of COVID-19 ICONA study group
OC 77 Predictors of mpox duration and severity in an Italian multicenter Cohort (Mpox-ICONA). V. Mazzotta, A. Tavelli, D. Moschese, A. Cozzi Lepri, F.M. Fusco, F. Colavita, L. Biasioli, A. Mondi, F. Carletti, A. Di Biagio, D. Mileto, G. Baldin, S. Nozza, L. Pipitò, D. Tesoro, N. Sangiovanni, E. Nicastri, G. Rizzardini, F. Maggi, A. d'Arminio Monforte, A. Antinori, S. Lanini
OC 79 SARS-CoV-2 mRNA vaccination and viro-immunological changes in PLWH. A. Vergori, A. Cozzi-Lepri, G. Marchetti, A. Tavelli, R. Gagliardini, G. Lapadula, N. Caroccia, L. Taramasso, A.M. Azzini, S. Lanini, F. Ceccherini-Silberstein, M. Giannella, E. Tacconelli, A. d’Arminio Monforte, A. Antinori, on behalf of VAX-ICONA Study Group
OC 118 Reasons for choosing a doravirine (DOR) based versus an INSTI-based regimen in ART-naïve and ART-experienced patients in real-world setting: data from ICONA Cohort. A. Saracino, M. Ponzano, F. Bovis, E. Quiros-Roldan, M. Fabbiani, N. Squillace, S. Rusconi, M. Ferrara, S. Lo Caputo, A. Tavelli, A. Antinori, A. d’Arminio Monforte
OC 135 Effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed persons living with HIV (PLWH): 96-week data from ICONA Cohort. A. d'Arminio Monforte, A. Tavelli, A. Cingolani, L. Taramasso, C. Mussini, S. Piconi, A. Calcagno, G. Orofino, S. Cicalini, A. Castagna, F. Ceccherini-Silberstein, A. Gori, G. Guaraldi, A. Antinori, for ICONA Foundation Study Group
OC 143 Impact of COVID-19 in time to linkage to care (LtC) and ART initiation in ICONA Cohort. P. Piselli, A. De Vito, A. Tavelli, C. Cimaglia, A. Nappo, M. Farinella, L. Rancilio, L. Cosmaro, C. Muccini, C. Santoro, D. Segala, M. Trizzino, A. Caraglia, A. d’Arminio Monforte, A. Antinori, E. Girardi, G. Madeddu, for ICONA Foundation Study Group and for the Working Group of the project “The impact of COVID-19 on the processes and outcomes of care of people with HIV”
OC 144 Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from ICONA network A. Giacomelli, R. Gagliardini, A. Tavelli, S. De Benedittis, V. Mazzotta, G. Rizzardini, A. Mondi, D. Barbanotti, S. Antinori, A. Vergori, A. Gori, M. Menozzi, L. Taramasso, F.M. Fusco, A. De Vito, G. Mancarella, G. Marchetti, A. d’Arminio Monforte, A. Antinori, A. Cozzi-Lepri, on behalf of COVID-19 ICONA study group
OC 146 Implementing an Electronic Patient-Reported Outcomes (ePROs) system in PLWH management: experience of Icona Cohort. A. Tavelli, L. Cosmaro, N. Gianotti, R. Gagliardini, V.G. Calvino, F. Bai, G. Guaraldi, F. Vichi, I. Fanti, M. Cernuschi, A. Antinori, A. d’Arminio Monforte, A. Cingolani
OC 150 Prevalence and outcome of Hepatitis Delta virus (HDV) infection among Persons Living with HIV (PLWH) in Italy: the Delta-Icona study. M. Puoti, R. Salpini, A. Tavelli, L. Piermatteo, S. D'Anna, S. Carrara, V. Malagnino, V. Mazzotta, G. Brancaccio, G.B. Gaeta, G Marchetti, E. Rosselli Del Turco, C.F. Perno, V. Svicher, A. d'Arminio Monforte, for Icona Foundation Study Group
Poster
P 4 Probability of starting 2DR vs 3DR regimens in ART-naïve and ART-experienced PLWH before and after the COVID-19 pandemic. A. Vergori, N. Gianotti, A. Tavelli, C. Tincati, A. Giacomelli, E. Matteini, G. Lapadula, F. Bai, L. Sarmati, A. d'Arminio Monforte, A. Antinori, A. Cozzi-Lepri, on behalf of ICONA Foundation Study Group
P 296 Quality of pre- and post-COVID-19 healthcare: the point of view of women living with HIV. A. Bove, M. Cernuschi, A. Cervo, C. Pinnetti, A. Perziano, M. Errico, G.V. Calvino, M. Giglia, M. Guastavigna, D. Canetti, A. Di Biagio, M.L. Cosmaro, A. Cingolani, for Icona Foundation Study Group